Is the activated partial thromboplastin time (aPTT) normal in patients with Factor V Leiden?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

aPTT in Factor V Leiden

Yes, the aPTT is normal in patients with Factor V Leiden. Factor V Leiden is a thrombophilic disorder that does not affect the intrinsic coagulation pathway measured by aPTT, and routine aPTT testing will not detect this mutation 1.

Why aPTT Remains Normal

  • Factor V Leiden involves a specific point mutation (R506Q) in the Factor V gene that makes Factor V resistant to inactivation by activated protein C, but does not affect the quantity or baseline function of Factor V in standard coagulation assays 1.

  • The aPTT measures the intrinsic and common coagulation pathways (factors XII, XI, IX, VIII, X, V, II, and fibrinogen), and Factor V Leiden patients have normal levels and baseline activity of these factors 2.

  • Standard aPTT testing cannot distinguish between normal Factor V and the mutant Factor V Leiden variant because both function normally in the absence of activated protein C 1.

Appropriate Testing for Factor V Leiden

The correct test for Factor V Leiden is either DNA-based genotyping or an activated protein C resistance (APC-R) assay, not aPTT 1, 3.

DNA-Based Testing (Preferred Method)

  • DNA-based genotyping is the gold standard with sensitivity of 98.8% and specificity of 99.3% 3.
  • This method can be performed on patients taking anticoagulants without interference 3.
  • DNA testing distinguishes between heterozygotes and homozygotes, which is clinically important since homozygotes have approximately 10-fold higher thrombotic risk 3.

APC-R Functional Assays

  • APTT-based APC-R assays with predilution in Factor V-deficient plasma have near 100% sensitivity and specificity for Factor V Leiden mutations 1.
  • These assays measure the prolongation of aPTT in response to added activated protein C—Factor V Leiden shows reduced prolongation (resistance) 1.
  • Modified APTT-based APC-R with predilution has 82% sensitivity for Factor V Leiden detection 4.

Clinical Implications

  • Do not rely on routine coagulation screening (PT, aPTT) to detect Factor V Leiden 5.
  • Factor V Leiden testing should be reserved for patients with venous thromboembolism where results may influence recurrence risk assessment and anticoagulation duration decisions 6.
  • Avoid reflexive thrombophilia testing in patients with arterial or retinal vascular occlusions without systemic thrombosis history 6.

Common Pitfalls to Avoid

  • Do not delay thrombophilia workup because aPTT is normal—this is expected in Factor V Leiden 1.
  • Do not order aPTT to screen for Factor V Leiden—it will not detect the mutation and may provide false reassurance 1, 5.
  • Avoid functional APC-R assays in patients on direct oral anticoagulants (DOACs)—these can falsely elevate APC-R ratios and miss the diagnosis; use DNA testing instead 1, 3.
  • Ensure proper sample collection—improper handling can cause spurious aPTT prolongation unrelated to any coagulation disorder 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Activated partial thromboplastin time.

Methods in molecular biology (Clifton, N.J.), 2013

Guideline

Typical Timeframe for Factor V Leiden Mutation Laboratory Results

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Factor V Leiden Testing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prolonged activated partial thromboplastin time in pregnancy: a brief report.

The American journal of the medical sciences, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.